Cencora, Inc.

COR Healthcare Medical Distribution

Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.

340.66 0.75 −0.22%
Market cap
$65.2B
P/E
25.2×
Fwd P/E
14.5×
Dividend yield
0.70%
F-score
6/9
Altman Z
4.83
Beneish M
−2.54
Dividend safety
74/100

Cencora, Inc. (COR) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Sep 24, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Aug 13, 2026 5.02 Departure or appointment of directors or officers
8-K Aug 12, 2026 7.01 Regulation FD disclosure
10-Q Jun 30, 2026 P1I2: 6 added · 5 removed · 47 modified
P2I1A: no material changes, the filing says
8-K Jul 31, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jun 10, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 23, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 21, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 17, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 5, 2026 5.07 Submission of matters to a vote of security holders
8-K Feb 17, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 13, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 10, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 10, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Dec 31, 2025 Impairment
8-K Feb 2, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 20, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Dec 12, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Sep 30, 2025 1: 2 added · 13 removed · 41 modified
1A: 14 added · 18 removed · 74 modified
7: 16 added · 12 removed · 67 modified
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 5, 2025 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Sep 3, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 27, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Sep 30, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.